A recent study conducted in the United States suggests that Novo Nordisk’s obesity drug, semaglutide (sold as Wegovy), not only aids in weight loss but also reduces the risk of heart disease. The study’s findings, presented at the European Congress on Obesity in Dublin, indicate…